Medicines labeled for the same conditions
Alternatives to imlunestrant
17 other medicines are given the same way (oral) and in the same FDA class as imlunestrant or labeled mainly for the same use (breast cancer); 1 is in its class, estrogen receptor antagonists: elacestrant; the others include 6 kinase inhibitors, 3 aromatase inhibitors and 2 estrogen agonist/antagonists (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as imlunestrant?
Breast cancer lists all 44 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Imlunestrantestrogen receptor antagonist | this medicine | none listed | n/a | No | No current entry |
| Elacestrantestrogen receptor antagonist · same class | Breast cancer | none listed | n/a | No | No current entry |
| Everolimusmtor inhibitor immunosuppressant | Breast cancer | 14 labelers | $26.32 per tablet 10 mg tablet | No | A presentation being discontinued |
| Anastrozolearomatase inhibitor | Breast cancer | 24 labelers | $0.142 per tablet 1 mg tablet | No | No current entry |
| Letrozolearomatase inhibitor | Breast cancer | 19 labelers | $0.145 per tablet 2.5 mg tablet | No | No current entry |
| Tamoxifenestrogen agonist/antagonist | Breast cancer | 10 labelers | $0.277 per tablet 20 mg tablet | Yes | No current entry |
| Exemestanearomatase inhibitor | Breast cancer | 10 labelers | $0.748 per tablet 25 mg tablet | No | No current entry |
| Talazoparibpoly(adp-ribose) polymerase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
| Palbociclibkinase inhibitor | Breast cancer | none listed | n/a | No | A presentation being discontinued |
| Abemaciclibkinase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
| Lapatinib ditosylatekinase inhibitor | Breast cancer | 3 labelers | n/a | Yes | No current entry |
| Olaparibpoly(adp-ribose) polymerase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
| Methyltestosteroneandrogen | Breast cancer | 2 labelers | n/a | No | No current entry |
| Ribociclibkinase inhibitor | Breast cancer | none listed | $289.72 per unit 600 mg daily dose | No | No current entry |
| Toremifeneestrogen agonist/antagonist | Breast cancer | 2 labelers | $19.60 per tablet 60 mg tablet | Yes | No current entry |
| Capivasertib | Breast cancer | none listed | n/a | No | No current entry |
| Tucatinibkinase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
| Neratinibkinase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Imlunestrant: the full record
- label, generics, price, shortages, recalls